Please Wait
Applying Filters...
menu
    • menu
    Cohance Lifesciences-PSE
    News
    Suven, Cohance to Double Business Revenue to Rs 6,000 Cr by FY29

    01 Nov 2024

    // ECONOMICTIMES

    Cohance Lifesciences merger with Suven Pharma gets NSE, BSE nod

    27 Jul 2024

    // TIMESOFINDIA

    Suven, with Cohance and more, wants to become a CDMO powerhouse

    02 Mar 2024

    // ECONOMIC TIMES

    Data Compilation
    #PharmaFlow

    Cohance Lifesciences

    Contact Supplier

    Website

    Pharma, Lab & Chemical Expo

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
    Menu

    Cohance Lifesciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-59687.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-62354.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-14233.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    FDF Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-35810.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-35932.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediate Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-40559.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Pellet Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-69896.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Antibody-Drug Conjugate Brochure 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-26405.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 6514

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3094

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Suven, Cohance to Double Business Revenue to Rs 6,000 Cr by FY29
    Suven, Cohance to Double Business Revenue to Rs 6,000 Cr by FY29

    01 Nov 2024

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/suven-cohance-aim-to-double-combined-business-revenue-to-rs-6000-cr-by-fy29/articleshow/114845104.cms

    ECONOMICTIMES
    01 Nov 2024
    Share Share
    Cohance Lifesciences merger with Suven Pharma gets NSE, BSE nod
    Cohance Lifesciences merger with Suven Pharma gets NSE, BSE nod

    27 Jul 2024

    // TIMESOFINDIA

    https://timesofindia.indiatimes.com/business/india-business/cohance-lifesciences-merger-with-suven-pharma-gets-nse-bse-nod/articleshow/112068320.cms

    TIMESOFINDIA
    27 Jul 2024
    Share Share
    Suven, with Cohance and more, wants to become a CDMO powerhouse
    Suven, with Cohance and more, wants to become a CDMO powerhouse

    02 Mar 2024

    // ECONOMIC TIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/suven-with-cohance-and-more-wants-to-become-a-cdmo-powerhouse-annaswamy-vaidheesh-executive-chairman/articleshow/108147698.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    ECONOMIC TIMES
    02 Mar 2024
    Share Share
    Suven-Cohance Lifesciences merger announced
    Suven-Cohance Lifesciences merger announced

    29 Feb 2024

    // PRESS RELEASE

    https://suvenpharm.com/pdf/events/SUVENPHAR_29022024190827_Suvenpharm_Pressrelease.pdf

    PRESS RELEASE
    29 Feb 2024
    Share Share
    Advent Launches New Brand For Its API Platform
    Advent Launches New Brand For Its API Platform

    04 Jan 2023

    // PRESS RELEASE

    https://cohance.com/advent-international-launches-new-brand-for-its-api-platform-2/

    PRESS RELEASE
    04 Jan 2023
    Share Share
    Advent launches Cohance Lifesciences, a new brand identity for its API platform
    Advent launches Cohance Lifesciences, a new brand identity for its API platform

    01 Nov 2022

    // PRESS RELEASE

    https://cohance.com/advent-international-launches-cohance-lifesciences-a-new-brand-identity-for-its-api-platform/

    PRESS RELEASE
    01 Nov 2022
    Share Share
    Contact Cohance Lifesciences and get a quotation

    Cohance Lifesciences is a supplier offers 106 products (APIs, Excipients or Intermediates).

    Find a price of Rivaroxaban bulk with DMF, CEP, JDMF, WC offered by Cohance Lifesciences

    Find a price of Aripiprazole bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Atomoxetin Hydrochloride bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Baclofen bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Clozapine bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Dapsone bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Dipyridamole bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Doxazosin Mesylate bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Entacapone bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Flurbiprofen bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Fluvoxamine bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Itraconazole bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Lamotrigine bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Midazolam bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Pirfenidone bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Quetiapine Hemifumarate bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Tamsulosin bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Venlafaxine Hydrochloride bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Verapamil Hydrochloride bulk with DMF, CEP, WC offered by Cohance Lifesciences

    Find a price of Zonisamide bulk with DMF, JDMF, WC offered by Cohance Lifesciences

    Find a price of Apixaban bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Articaine Hydrochloride bulk with CEP, WC offered by Cohance Lifesciences

    Find a price of Betahistine Dihydrochloride bulk with CEP, WC offered by Cohance Lifesciences

    Find a price of Dapagliflozin Propanediol Monohydrate bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Diflunisal bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Hydralazine Hydrochloride bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Levocetirizine Dihydrochloride bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Levomepromazine Maleate bulk with CEP, WC offered by Cohance Lifesciences

    Find a price of Lurasidone Hydrochloride bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Mebeverine bulk with CEP, WC offered by Cohance Lifesciences

    Find a price of Memantine Hydrochloride bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Methylphenidate Hydrochloride bulk with CEP, WC offered by Cohance Lifesciences

    Find a price of Mexiletine bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Piribedil bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Posaconazole bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Ticagrelor bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of Zonisamide bulk with DMF, WC offered by Cohance Lifesciences

    Find a price of 7-Ethyl-10-Hydroxycamptothecin bulk with DMF offered by Cohance Lifesciences

    Find a price of Atomoxetin Hydrochloride bulk with CEP offered by Cohance Lifesciences

    Find a price of CAS 160707-37-9 bulk with DMF offered by Cohance Lifesciences

    Find a price of CAS 19982-07-1 bulk with DMF offered by Cohance Lifesciences

    Find a price of Drotaverine bulk with WC offered by Cohance Lifesciences

    Find a price of Empagliflozin bulk with DMF offered by Cohance Lifesciences

    Find a price of Epinastine Hydrochloride bulk with WC offered by Cohance Lifesciences

    Find a price of Eslicarbazepine Acetate bulk with DMF offered by Cohance Lifesciences

    Find a price of Ferric Citrate bulk with DMF offered by Cohance Lifesciences

    Find a price of Fomepizole bulk with WC offered by Cohance Lifesciences

    Find a price of Lamotrigine bulk with CEP offered by Cohance Lifesciences

    Find a price of Levodropropizine bulk with CEP offered by Cohance Lifesciences

    Find a price of Maraviroc bulk with DMF offered by Cohance Lifesciences

    Find a price of Meclizine Hydrochloride bulk with DMF offered by Cohance Lifesciences

    Find a price of Menthadienol bulk with DMF offered by Cohance Lifesciences

    Find a price of Metaxalone bulk with DMF offered by Cohance Lifesciences

    Find a price of Midazolam Hydrochloride bulk with WC offered by Cohance Lifesciences

    Find a price of Midazolam Maleate bulk with WC offered by Cohance Lifesciences

    Find a price of Mirabegron bulk with DMF offered by Cohance Lifesciences

    Find a price of Olivetol bulk with DMF offered by Cohance Lifesciences

    Find a price of Oxolamine Citrate bulk with WC offered by Cohance Lifesciences

    Find a price of Oxolamine Phosphate bulk with WC offered by Cohance Lifesciences

    Find a price of Ritalinic Acid bulk with DMF offered by Cohance Lifesciences

    Find a price of S-trione bulk with DMF offered by Cohance Lifesciences

    Find a price of Tapentadol Phosphate bulk with WC offered by Cohance Lifesciences

    Find a price of Tolcapone bulk with DMF offered by Cohance Lifesciences

    Find a price of Vanillylamine bulk with DMF offered by Cohance Lifesciences

    Find a price of Levomepromazine Maleate bulk offered by Cohance Lifesciences

    Find a price of Belotecan bulk offered by Cohance Lifesciences

    Find a price of Bempedoic Acid bulk offered by Cohance Lifesciences

    Find a price of Benserazide Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Brivudine bulk offered by Cohance Lifesciences

    Find a price of Buspirone bulk offered by Cohance Lifesciences

    Find a price of Cannabidiol bulk offered by Cohance Lifesciences

    Find a price of Cilostazol bulk offered by Cohance Lifesciences

    Find a price of Dabigatran Etexilate Mesylate bulk offered by Cohance Lifesciences

    Find a price of Desvenlafaxine Succinate bulk offered by Cohance Lifesciences

    Find a price of Dexlansoprazole bulk offered by Cohance Lifesciences

    Find a price of Dexmethylphenidate bulk offered by Cohance Lifesciences

    Find a price of Duloxetine Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Esomeprazole Magnesium bulk offered by Cohance Lifesciences

    Find a price of Exatecan bulk offered by Cohance Lifesciences

    Find a price of Fenofibrate bulk offered by Cohance Lifesciences

    Find a price of Galantamine Hydrobromide bulk offered by Cohance Lifesciences

    Find a price of Irinotecan Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Lansoprazole bulk offered by Cohance Lifesciences

    Find a price of Lenalidomide bulk offered by Cohance Lifesciences

    Find a price of Lercanidipine bulk offered by Cohance Lifesciences

    Find a price of Lisdexamfetamine Dimesylate bulk offered by Cohance Lifesciences

    Find a price of Loxoprofen Sodium bulk offered by Cohance Lifesciences

    Find a price of Methotrexate bulk offered by Cohance Lifesciences

    Find a price of Metoprolol Tartrate bulk offered by Cohance Lifesciences

    Find a price of Miglustat bulk offered by Cohance Lifesciences

    Find a price of Monomethyl Auristatin E bulk offered by Cohance Lifesciences

    Find a price of Monomethyl Auristatin F bulk offered by Cohance Lifesciences

    Find a price of Moxonidine bulk offered by Cohance Lifesciences

    Find a price of Omeprazole bulk offered by Cohance Lifesciences

    Find a price of Orlistat bulk offered by Cohance Lifesciences

    Find a price of Oxymetazoline Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Propiomazine Maleate bulk offered by Cohance Lifesciences

    Find a price of Ractopamine Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Remimazolam Besylate bulk offered by Cohance Lifesciences

    Find a price of Rubitecan bulk offered by Cohance Lifesciences

    Find a price of Silatecan bulk offered by Cohance Lifesciences

    Find a price of Topotecan Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Trazodone Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Trimebutine Maleate bulk offered by Cohance Lifesciences

    Find a price of Trimetazidine bulk offered by Cohance Lifesciences

    Find a price of Vildagliptin bulk offered by Cohance Lifesciences